Bristol-Myers Squibb Short Interest Up 12.3% in July (BMY)
Bristol-Myers Squibb (NYSE:BMY) saw a large growth in short interest in July. As of July 31st, there was short interest totalling 31,907,283 shares, a growth of 12.3% from the July 15th total of 28,406,470 shares, Stock Ratings Network.com reports. Based on an average trading volume of 7,436,236 shares, the short-interest ratio is presently 4.3 days. Currently, 1.9% of the company’s stock are sold short.
A number of research firms have recently commented on BMY. Analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb from $43.50 to $45.00 in a research note on Monday. They now have a “hold” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Bristol-Myers Squibb in a research note on Friday, July 25th. They now have a $52.00 price target on the stock. Finally, analysts at MKM Partners raised their price target on shares of Bristol-Myers Squibb from $29.00 to $34.00 in a research note on Friday, July 25th. They now have a “sell” rating on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $51.81.
Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 49.82 on Friday. Bristol-Myers Squibb has a one year low of $41.11 and a one year high of $57.49. The stock has a 50-day moving average of $49.12 and a 200-day moving average of $50.41. The company has a market cap of $82.597 billion and a P/E ratio of 30.54.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Thursday, July 24th. The company reported $0.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.04. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter last year, the company posted $0.44 earnings per share. Bristol-Myers Squibb’s revenue was down 3.9% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb will post $1.81 EPS for the current fiscal year.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with Analyst Ratings Network's FREE daily email newsletter.